Aspire BioPharma, Inc. (ASBP) — Working Capital to Net Assets Ratio
Aspire BioPharma, Inc. (ASBP) has a Working Capital to Net Assets ratio of 102.5% as of March 2026. Working capital of $3.96 Million (current assets of $7.12 Million minus current liabilities of $3.15 Million) is measured against net assets of $3.87 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Aspire BioPharma, Inc. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Aspire BioPharma, Inc. Working Capital to Net Assets (2021–2025)
This chart shows how Aspire BioPharma, Inc.'s Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of March 2026, the ratio stands at 102.5%, reflecting working capital of $3.96 Million against net assets of $3.87 Million USD. For the complete balance sheet picture, see total assets of Aspire BioPharma, Inc..
Annual Working Capital to Net Assets for Aspire BioPharma, Inc. (2021–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Aspire BioPharma, Inc. from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read Aspire BioPharma, Inc. debt and liabilities for a breakdown of total debt and financial obligations.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 98.5% | $-6.28 Million | $-6.38 Million | $1.31 Million | $7.59 Million | ▼ -1.5 pp |
| 2024 | 100.0% | $-1.54 Million | $-1.54 Million | $147.99K | $1.69 Million | ▲ +101.6 pp |
| 2023 | -1.6% | $-322.11K | $19.58 Million | $81.22K | $403.33K | ▼ -1.9 pp |
| 2022 | 0.3% | $794.43K | $289.07 Million | $1.10 Million | $303.32K | ▼ -99.7 pp |
| 2021 | 100.0% | $-475.00 | $-475.00 | $293.22K | $293.70K | — |